Gilead Sciences stock jumps on HIV treatment trial success [Yahoo! Finance Canada]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Yahoo! Finance Canada
results for its HIV treatment trial, claiming it's the first Phase 3 HIV prevention trial ever to show zero Infections. Market Domination Anchors Josh Lipton and Julie Hyman break down the latest development for Gilead Sciences and what it could mean for the company moving forward For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Nicholas Jacobino Video Transcript Now let's get to some trending tickers. First of Gilead Sciences. The shares of 8% after announcing that it's experimental twice yearly medicine to prevent HIV demonstrate demonstrated 100% efficacy for the investigation. Use in cisgender women in Africa, women and adolescent girls. So the company has some, um, medications on the market already. Um, but they either are daily oral. Or perhaps you have to do them as shots every months, so this is less frequent. So the hope is, is that this will be there will be more
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- NEW DATA SUPPORT THE USE OF BICTEGRAVIR TABLET REGIMEN TO TREAT PEOPLE WITH HIV AND INDIVIDUALS WITH HIV/HBV-COINFECTION IN ASIA [Yahoo! Finance]Yahoo! Finance
- Recent uptick might appease Gilead Sciences, Inc. (NASDAQ:GILD) institutional owners after losing 4.6% over the past year [Yahoo! Finance]Yahoo! Finance
- Global Autologous Stem Cell & Non-Stem Cell Therapies Market: $5.5B in 2024 to $22.2B by 2029, CAGR 32.3% | MarketsandMarkets™ [Yahoo! Finance]Yahoo! Finance
- GILEAD'S TWICE-YEARLY LENACAPAVIR DEMONSTRATED 100% EFFICACY AND SUPERIORITY TO DAILY TRUVADA® FOR HIV PREVENTION [Yahoo! Finance]Yahoo! Finance
- Oruka Therapeutics Announces Key Additions to Leadership Team and Board of Directors [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 4/25/24 - Beat
GILD
Sec Filings
- 6/11/24 - Form 4
- 6/11/24 - Form 4
- 6/11/24 - Form 4
- GILD's page on the SEC website